Some reports have described a high rate (29%) of HNSCC patients experiencing hyperprogression during immunotherapy treatment, which is detected as an acceleration of the tumor growth kinetics upon therapy with PD-1/PD-L1 inhibitors [24,26]. The gene discussed is CD274; the disease is neoplasm.